RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
  Brain Diseases
  Demyelinating Diseases
  Headache
  Memory
  Neurochemistry
  Neurodegenerative Diseases
  Regeneration
  Spinal Cord Diseases
  Stroke
  Taste
  Trigeminal Neuralgia
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Neurosciences Channel

subscribe to Neurosciences newsletter
Latest Research : Neurosciences

   EMAIL   |   PRINT
Wasabi's kick linked to TRPA1 pain receptor

Mar 27, 2006 - 12:28:00 AM , Reviewed by: Priya Saxena
"We identified TRPA1 (the receptor) not only as a promising target for the development of new pain medications, but also for potential new treatments of smoking-related disease and environmental irritation,"

 
[RxPG] A single pain receptor is responsible for the kick delivered by garlic and mustard oil, which is the active ingredient in mustard and in the pungent green sushi condiment known as wasabi, according to a Yale School of Medicine study published this week in Cell.

The sensory receptor also underlies the response to a variety of environmental irritants, such as acrolein, the researchers report. Acrolein accounts for the toxic and inflammatory actions of tear gas, vehicle exhaust, tobacco smoke, and the byproduct of some chemotherapy drugs widely used in the treatment of cancer, severe arthritis, multiple sclerosis, and lupus.

"We identified TRPA1 (the receptor) not only as a promising target for the development of new pain medications, but also for potential new treatments of smoking-related disease and environmental irritation," said Sven-Eric Jordt, co-author and assistant professor in the Department of Pharmacology at Yale.

The researchers examined whether neurons taken from mice lacking the TRPA1 receptor responded normally to the pungent compounds found in mustard oil and garlic. They found neurons from the TRPA1-deficient mice were completely insensitive to either ingredient. In fact, the animals lacking the sensory gene did not flinch or try to lick when mustard oil was applied to their paws. Their paws also swelled less and became less sensitive to pain in response to the mustard oil exposure.

The team also found that TRPA1 is an important target of bradykinin, one of the body's natural inflammatory agents that stimulates pain-sensing neurons and leads to hypersensitivity to heat or touch.

Mice lacking the TRPA1 channel had a normal ability to sense extreme cold and noxious sound, evidence against the suggestions of earlier studies that the channels might also play important roles in cold sensitivity or hearing, they found.

"Pain therapy is one of the major challenges in modern medicine," said Jordt. "Currently, 20 percent of all Americans suffer from chronic or inflammatory pain, associated with arthritis, back injuries, headaches, migraines, and shingles."

"Although we are beginning to understand more about the causes of pain, the pharmacological repertoire of pain medications is still very limited. Most of the chemical substances from which current pain therapeutics are derived were discovered more than 100 years ago," he said. "Thus, the development of new pain medications is urgently needed to fill the therapeutic gaps and to treat additional forms of pain."



Publication: Cell 124: 1-14 (March 23, 2006)
On the web: www.yale.edu 

Advertise in this space for $10 per month. Contact us today.


Related Neurosciences News
A new tool for brain research
Eve Marder to receive the $500,000 Gruber Neuroscience Prize
Research teams find genetic variant that could improve warfarin dosing in African-Americans
Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases
Study identifies a genetic risk factor for persistent pain
New BRAIN initiative announced at White House
Nurses can play key role in reducing deaths from world's most common diseases
UH Case Medical Center awarded highest certification as Comprehensive Stroke Center
NIH funds research to identify Parkinson's biomarkers
Treatment with clot-busting drug yields better results after stroke than supportive therapy alone

Subscribe to Neurosciences Newsletter

Enter your email address:


 Additional information about the news article
Co-authors include Diana Bautista, Tetsuro Nikai, Pamela Tsuruda, Jeannie Poblete, Allan Basbaum, and David Julius, of the University of California at San Francisco; Ebenezer Yamoah of the University of California at Davis, and Andrew Read of Yale.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)